Search Bar & Filters
Found 21 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.
Actively Recruiting
Researchers are studying the safety, tolerability, and best dosing of a drug called ABT-301 combined with fixed doses of tislelizumab and bevacizumab in adults with a type of colorectal cancer called proficient mismatch repair pMMRnon-microsatellite instability-high non-MSI-H colorectal cancer. This study aims to find the highest safe dose of ABT-301 and the recommended dose for future studies while evaluating its effects in advanced or metastatic cases. Participants will take ABT-301 orally either once or twice daily in 21-day treatment cycles. Alongside ABT-301, participants will receive tislelizumab 200 mg and bevacizumab 7.5 mgkg via intravenous infusion on the first day of each 21-day cycle. The study has two parts a dose-escalation phase to identify safe dosing levels and a dose-optimization phase to further evaluate two selected doses for safety and activity against the cancer. During the study, participants will undergo regular assessments including measuring tumor response using RECIST criteria, monitoring safety and side effects, and pharmacokinetic and pharmacodynamic evaluations. These assessments occur from screening through treatment and up to 90 days after the last dose or until disease progression or death, lasting up to 28 months. The study monitors overall survival, progression-free survival, and duration of response to treatment.
Actively Recruiting
The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.
Actively Recruiting
Researchers are evaluating the safety and tolerability of an investigational drug called elritercept, both alone and in combination with the JAK inhibitor ruxolitinib, in adults with myelofibrosis MF. The study also aims to understand how elritercept affects the signs and symptoms of MF, how the body processes the drug, and its effects on anemia when used with or without ruxolitinib. This is a Phase 2 open-label study focusing on participants with anemia related to MF.
Actively Recruiting
Researchers are studying the safety, tolerability, and preliminary anti-tumor effects of oral GFH276 combined with cetuximab or standard chemotherapy in adults with locally advanced or metastatic RAS-mutated solid tumors and pancreatic ductal adenocarcinoma PDAC. This open-label, multicenter Phase IbII trial aims to find the best dose for further study and evaluate treatment outcomes in this patient group. Participants will be assigned to one of three treatment groups GFH276 with cetuximab given intravenously every two weeks, GFH276 with nab-paclitaxel plus gemcitabine on cycles of three or four weeks, or GFH276 with mFOLFIRINOX chemotherapy given every two weeks. The Phase Ib stage involves increasing GFH276 doses to identify dose-limiting toxicities and safety, followed by Phase II expansion to assess anti-tumor effectiveness and long-term safety of each combination. During the study, participants will undergo tumor imaging, laboratory tests, adverse event monitoring, and blood sampling to study drug levels. Treatment continues until disease worsens, unacceptable side effects occur, consent is withdrawn, or the study ends. Safety and response will be followed for up to 24 months, with detailed assessments of adverse events, tumor response, and pharmacokinetics included.
Actively Recruiting
Researchers are evaluating the efficacy and safety of belimumab compared to placebo, both given alongside standard therapy, for adults with systemic sclerosis associated interstitial lung disease SSc-ILD. The study aims to assess how belimumab affects lung function and other disease features such as skin thickening and symptoms like fatigue that influence quality of life. Participants will be randomly assigned to receive either belimumab or a placebo, both in addition to their usual therapy. Belimumab is given by subcutaneous injection. The study measures various health outcomes at baseline and after 52 weeks, including lung capacity, skin condition, fatigue, and disease progression. Throughout the study, participants will undergo scans, lung function tests, skin assessments, and questionnaires about symptoms and quality of life. Researchers will monitor adverse events and disease markers to evaluate treatment impact and safety over the 52-week period.
Actively Recruiting
Non-small cell lung cancer NSCLC is a common lung cancer type where abnormal lung cells grow uncontrollably. This research evaluates the safety, optimal dose, and effect on disease activity of telisotuzumab adizutecan combined with osimertinib Osi compared to standard care in adults with locally advanced or metastatic EGFR-mutated non-squamous NSCLC. The study is conducted in two stages across about 76 months and includes approximately 854 participants worldwide. In the first stage, participants receive escalating intravenous doses of telisotuzumab adizutecan alongside oral osimertinib tablets or the standard care regimen of osimertinib plus chemotherapy. After dose escalation, participants are randomized into four treatment arms receiving different doses of telisotuzumab adizutecan with osimertinib or standard care. The second stage involves treatment with the optimal telisotuzumab adizutecan dose combined with osimertinib or standard care for the study duration. Participants attend regular visits at approved hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor side effects and treatment effects. Researchers measure outcomes including tumor response, progression-free survival, and adverse events over the approximately 76-month study period. Quality of life and lung cancer symptom changes are also evaluated during treatment to assess overall impact.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of standard chemotherapy with or without the drug INCB161734 in people with metastatic pancreatic ductal adenocarcinoma PDAC that has a specific KRAS G12D mutation. This is a Phase 3 randomized, double-blind trial aiming to compare these treatments in patients who have not received prior systemic treatment for their metastatic cancer. Participants will receive either oral INCB161734 tablets or placebo tablets alongside chemotherapy chosen by the investigator, either mFOLFIRINOX or GemNabP, as per the study protocol. The study compares these two groups to assess outcomes such as survival and response to treatment. Treatment and observation will continue for up to approximately two to three years depending on the outcome being measured. During the trial, participants will undergo regular assessments including survival monitoring, tumor response evaluations by blinded independent central review and investigator assessments, and quality of life questionnaires. Researchers will also monitor adverse events and organ function. The study involves scheduled visits and tests over the course of treatment and follow-up lasting up to several years to understand long-term effects and treatment impact.
Actively Recruiting
Metastatic colorectal cancer mCRC is the focus of this study, which evaluates the safety and disease activity changes when telisotuzumab adizutecan is combined with oxaliplatin, fluorouracil 5FU, leucovorin LV, bevacizumab, or panitumumab. This phase 2 trial aims to assess adverse events and efficacy of these combinations in adults with mCRC, addressing an important cancer type with high incidence, especially in developed countries. The study has two main parts a dose escalation phase and a dose optimization phase. In the dose escalation phase, participants receive increasing intravenous doses of telisotuzumab adizutecan alongside FOLFOX fluorouracil, leucovorin, oxaliplatin with bevacizumab or 5FULV with panitumumab until a tolerable and potentially effective dose is identified. In the dose optimization phase, participants are randomized to receive either one of two optimized doses of telisotuzumab adizutecan combined with FOLFOX and bevacizumab or 5FULV and panitumumab, or the comparator treatment of FOLFOX with bevacizumab or panitumumab. This study is planned to last about six years and will enroll approximately 390 adults worldwide. Participants will attend regular visits at approved hospitals or clinics for treatment and monitoring throughout the study. Researchers will perform frequent medical assessments including blood tests, questionnaires, and monitor side effects to evaluate treatment impact. The main outcomes studied include objective response rate complete or partial tumor response within 24 weeks and adverse events over approximately six years. Additional outcomes like progression-free survival, duration of response, overall survival, and disease control are also tracked to understand treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of subcutaneous anifrolumab injections compared to placebo in adults with moderate to severe Idiopathic Inflammatory Myopathies IIM, including polymyositis PM and dermatomyositis DM. This Phase III, multicenter, randomized, placebo-controlled, and double-blind study adds anifrolumab or placebo to participants standard of care treatment to assess overall disease activity. Participants receive either anifrolumab or a matched placebo by subcutaneous injection once weekly for 52 weeks while continuing their standard treatments. After this period, all participants have the option to receive open-label anifrolumab weekly for an additional 52 weeks. This design allows researchers to compare the effects of anifrolumab against placebo and then observe longer-term effects when all receive anifrolumab. Throughout the study, participants undergo regular assessments including the Total Improvement Score TIS at 52 weeks as the main outcome. Additional evaluations include muscle strength testing, corticosteroid dosage monitoring, skin disease activity, and itch severity up to 52 weeks. Safety and disease activity improvements for both PM and DM participants are closely monitored. The study lasts up to approximately two years, including both blinded and open-label treatment phases.
1-10 of 21
1